The Microgenics CEDIA DAU (ElM and the Abbott AxSym system (FPIA) cannabinoids assays were evaluated for their combined effectiveness in the analysis of cannabinoids in whole blood. Blood samples were treated with acetone, evaporated, and reconstituted, and the supernatant was analyzed by the EIA cannabinoids assay. Blood samples determined positive by EIA were then treated with acetonitrile and sodium sulfate, and the resultant protein4ree supernatant was analyzed using the FPIA cannabinoids assay. A total of 98 blood samples determined to be presumptively positive by both EIA and FPIA were further analyzed for the presence of 11-nor-carboxy-A%tetrahydrocannabinol-9-carboxylic acid (THCCOOH). All 98 blood samples could be confirmed for the presence of THCCOOH by gas chromatography-mass spectrometry (GC-MS) at concentrations greater than the 10 ng/mL cutoff. The GC-MS results were found to correlate significantly better with those of the FPIA cannabinoids assay (r = 0.75) than with EIA (r--0.22). Procedures for the rapid analysis of whole blood for cannabinoids using CEDIA DAU reagents and the AxSym system are presented.
Introduction
Immunoassay procedures developed primarily for urine have been successfully adapted to the analysis of whole blood by a number of investigators (1) (2) (3) (4) (5) (6) (7) (8) . The acetone precipitation method for the analysis of whole blood by immunoassay has been used in our laboratory for over 8 years and continues to be the method of choice, although several refinements have been made since this method was first reported (1) . This original method was developed for the EMIT TM enzyme immunoassays (EIA) and now has been extended to analysis with Microgenics CEDIA immunoassays.
Relatively few procedures have been reported for the analysis of marijuana in whole blood using immunoassay. Childs and McCurdy (9) first reported the use of Roche Abuscreen TM radioimmunoassay (RIA) for the analysis of cannabinoids in blood. The efficacy of this procedure has since been corroborated by several other investigators (10, 11) and has been a very useful adjunct in our laboratory for the analysis of total cannabinoids in blood and other drugs for many years. RIA results in combination with the EIA results proved to be a very reliable indicator of marijuana use. However, in the interest of employing techniques that use nonradioactive materials, we recently investigated the use of fluorescence polarization immunoassay (FPIA) rather than RIA to further corroborate the presumptive findings of marijuana in blood by EIA.
The Abbott ADx system was initially considered for the FPIA analysis of marijuana in blood, but it was determined to be too limiting in the number of specimens it can analyze at one time. We elected instead to use the highly automated, computer-controlled AxSym system, which allows for the analysis of substantially more specimens at a much faster throughput. A variety of solvents were then investigated as a means to derive a clear supernatant for analysis by FPIA. Most of the solvents attempted gave either inconsistent results or no results at all because some solvents reacted with the sample cups. One of the initially successful methods was to employ a 1:1 mixture of blood and a 5% aqueous solution of dimethyl sulfoxide (DMSO). This procedure, unfortunately, gave readings of very low intensity, and only the "Net P" results from the AxSym instrument were obtainable. Although plotting such results against concentration could give acceptable, albeit indirect, semiquantitative results for total cannabinoids in blood, this procedure was considered less than desirable. Eventually, a more suitable and reliable method was found by simply employing a 1:2 mixture of blood and acetonitrile. The supernatant from this protein precipitation procedure was sufficiently clear that the instrument was able to print a direct quantitative value instead of a "Net P" result.
Material and Methods

Instrumentation
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Reagents
All solvents were of reagent-grade quality. The buffer (pH 7.0 Tris) was from Syva Company (San Jose, CA). CEDIA immunoassay reagents were supplied by Microgenics. Reagents for the AxSym were supplied by Abbott. Except for the different matrices used, all procedures for the preparation of the immunoassay reagents were the same as those recommended by the manufacturer for the analysis of urine.
Procedures
Screening procedure. The procedure for the extraction of common drugs of abuse (barbiturates, benzodiazepines, cocaine, opiates, amphetamines, and cannabinoids) from blood and analysis by EIA was modified substantially from the previously reported screening procedure (1). Acetone (2.5 mL) was added to appropriately 100 -labeled disposable glass test tubes (16 x 125). While vortex mixing, 1 mL of case 90 -blood, calibrator, or control was added to 80 -the center of the vortex, after which the tubes were allowed to stand for approxi-70 ~--mately 10 min. The tubes were then vortex mixed for another 15 s and centrifuged for ,,., 60 -10 rain at 2500 xg. The supernatant was de-50 --canted into a clean glass test tube (16 x 125) through an empty solid-phase extraction 40 -(SPE) column fitted with a 10-1Jm frit. The 30 -frit was then washed with 0.5 mL acetone and the washings were added to the super-20 -natant. Methanolic HCI (50 I~L of a 1% solution) was then added to each tube, and the tubes were briefly vortex mixed. The addition of acid was necessary to prevent the loss of amphetamines during the drydown step, but at the same time it caused an approximately 30% loss of cannabinoids. This step may be omitted if it is desired that 250 -the yield of cannabinoids be fully maximized, but doubling the sample volumes from 3 to 6 IJL in the Hitachi 911 setup suf-200 -ficiently compensated for any losses that were due to the addition of acid. The tubes < 150 -were then placed into a TurboVap and evap-E" orated to dryness at 75~ for exactly 20 min. u_
--
The time for the dry-down step was precisely controlled to help minimize the loss of cannabinoids. The residue was then 50 -reconstituted in 0.5 mL of a 1:1 mixture of EMIT buffer and methanol. The mixture was vortex mixed briefly, and the tubes were 0 -centrifuged for 10 min. The supernatant was transferred to an immunoassay cup, taking care not to disturb any pellet that might be at the bottom of the tube. Negative and cutoff calibrators (25 ng/mL) were processed simultaneously. Additionally, negative and positive controls (0 and 40 ng/mL, respectively) to equal 10% of the batch were also processed simultaneously. All specimens screening presumptively positive by EIA for marijuana were then further analyzed using the AxSym system (FPIA).
AxSym system. Case blood, calibrator, or control (0.5 mL) was added dropwise to 1.0 mL acetonitrile and 200 ]JL of a saturated solution of sodium sulfate in water in a disposable glass test tube (12 x 100) while vortex mixing. After the blood was added, the tubes were vortex mixed for another 20 s. The tubes were allowed to sit for approximately 5 rain, and then vortex mixed for another 20 s. The tubes were then centrifuged for 10 min at 2500 xg, and the top layer was decanted into an AxSym sample cup. Calibrators were processed simultaneously to generate a 6-point standard curve from 25 to 250 ng/mL. A negative control (0 ng/mL) and a positive control (50 ng/mL) to equal 10% of the batch were also processed simultaneously. Selection of blood samples for confirmation. Of the numerous blood samples analyzed by the combination of the two immunoassays, 98 positive blood samples were selected to be confirmed by gas chromatography-mass spectrometry (GC-MS). The primary criteria was that the blood sample must have an EIA and FPIA result at or above the assigned cutoffs of 25 ng/mL. It should be noted that the FPIA cutoff initially used in this GC-MS study was not the same as the cutoff concentration currently being used (see Discussion). The selection of blood samples to be confirmed by GC-MS analysis was more or less entirely at random with the main criterion being that there must be sufficient amount of sample to conduct the analysis. Other, somewhat less important, selection criteria were the blood samples selected should vary, as much as possible, in their immunoassay concentrations and in the different types of blood containers. In addition, two blood specimens that were previously determined to be negative for marijuana were also selected for GC-MS analysis and served as blind negative controls.
GC-MS. The GC-MS procedure to test for the presence of 11-nor-carboxy-Ag-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) was based on a previously published report for the analysis of marijuana in plasma (12) . A standard curve was generated using a 5-point standard curve from 10 to 200 ng/mL. The cutoff positive calibrator was 10 ng/mL. The correlation coefficient for each standard curve generated was 0.998 or greater. Results for the 98 blood samples analyzed by CEDIA (EIA), AxSym (FPIA), and GC-MS are shown in Table I . It should be noted that one blood sample that gave a GC-MS result of 383 ng/mL was omitted from any calculations comparing immunoassays, especially FPIA, with GC-MS. In this particular specimen, the FPIA result was quantitated at a concentration much higher than 250 ng/mL, and, because the FPIA result was not precisely known, no reasonable comparisons between FPIA and GC-MS could be made.
Results and
Plotting the EIA results versus the FPIA results showed that there is little correlation between the two immunoassays (r = 0.21). Plotting EIA versus GC-MS also demonstrated little correlation (r = 0.22), as shown in Figure 1 . Figure 2 shows the FPIA results plotted against GC-MS results, which demonstrated a much better correlation with a correlation coefficient of 0.75.
A typical standard curve for the linear portion of the EIA analysis curve for THCCOOH in blood is shown in Figure 3 . When employing the methods described herein for the analysis of cannabinoids by EIA, the upper limit of linearity for the cannabinoids assay is about 50 ng/mL. The slope of this curve rapidly falls off to essentially zero for a THCCOOH concentration of approximately 75 ng/mL. The linear portion of the standard curve for FPIA analysis of THCCOOH in whole blood using our method is shown in Figure 4 . The upper range for linearity of FPIA can be considerably higher, approximately 150 ng/mL, after which the slope of the curve gradually falls to near zero at about 250 ng/mL. Thus, FPIA has the appearance of having a dynamic linear range at least three times that of EIA, but it should be noted that the reason for the observed disparity may be exclusively due to the differences in the methods employed for the isolation of the cannabinoids from whole blood. Because the cross-reactivities for cannabinoids between the two immunoassays appear to be comparable, this alone would not account for the observed differences in the dynamic linear ranges.
As indicated previously, the positive cutoff calibrator for EIA was 25 ng/mL. Because the precision at the cutoff for EIA was somewhat greater than is usually considered desirable (coefficient of variation [CV] = 17%), it was decided that more stringent criteria should be applied to FPIA at the cutoff. Analysis of replicate samples by FPIA at the EIA cutoff of 25 ng/mL demonstrated, like EIA, a CV of greater than 10%. However, increasing the concentration to approximately 50% above the cutoff (35 ng/mL) yielded much more acceptable CVs (< 10%) for replicate analyses; therefore, the cutoff calibrator for FPIA was established at 35 ng/mL. It should be noted that this cutoff was established after the GC-MS studies had already been conducted. Therefore, there are 15 samples in Table I that quantitate at less than the current FPIA cutoff calibrator of 35 ng/mL. Because all 15 samples could be confirmed by GC-MS at greater than 10 ng/mL, they were included in this study. It is conceivable that when more data have been collected and techniques become more refined, that FPIA cutoff could be reliably reduced to 25 ng/mL.
Conclusion
The combination of CEDIA reagents and AxSym reagents was shown to be a powerful tool for the presumptive identification of cannabinoids in whole blood. When the two assays are in agreement, we have shown that 100% of the 98 cases selected at random may be confirmed at greater than 10 ng/mL THCCOOH. Undoubtedly, either one of the two immunoassays can be moderately effective in establishing a presumptive positive for cannabinoids in whole blood. However, the success rate for the confirmation of cannabinoids in blood using a single assay should not be expected to match the success rate using a combination of the two assays.
